WEP Clinical (WEP) announced today that, as of July 2020, it has started a new Named Patient Program (NPP) on behalf of a US biotech company specializing in developing and commercializing novel oncology therapies. Under the terms of the NPP, WEP will manage the supply and distribution of the company’s FDA-approved cancer product to physicians outside the US to treat their patients.
The NPP will provide continued treatment access to former clinical trial patients and will also provide access to new patients, with an unmet clinical need, who meet the necessary eligibility criteria. The treatment will be made available in two strengths and will be provided on a compassionate use basis to enable healthcare professionals around the world to access this important treatment for their patients.
For further information on WEP’s Named Patient Programs, please email us or visit our website:
About WEP Clinical
Established in 2008, WEP is a specialist pharmaceutical services company that works with sponsors to help patients and physicians gain access to medicines when there is no treatment available in their country. WEP Clinical is a global organisation and possesses all necessary licenses required to meet drug access and distribution needs across all regions, worldwide.